Acadia Pharmaceuticals
acadia-pharm.com · Healthcare · ACAD
Ranked 1,184 of 2,047 companies in the study
- Visibility0
- Citations15
- Sentiment50
- Site quality87
- AI readiness29
AI assistants do not name Acadia Pharmaceuticals in any of their answers across 60 questions. Its overall score is 31 out of 100, which ranks 1,184th of 2,047 companies in the study. The website passes 2 out of 14 technical checks for readiness with AI tools.
We asked 15 unbranded questions about the healthcare market: none named Acadia Pharmaceuticals. AI assistants named it in none of 60 answers. The typical healthcare company is named in 3.3% of answers. By how often it is named, Acadia Pharmaceuticals ranks 69 of 105 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationPassed
Requests sent with Accept: text/markdown receive a markdown version of the page.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 36 of 100 · 97% of checks could run · checked on October 5, 2026 · acadia.com · 2,047 companies scanned
2 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Not metrobots.txt publishedstudy: 85.0%
- Not metXML sitemapstudy: 73.2%
- Not metHTTP Link headers (RFC 8288)study: 29.0%
- PassedMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
How many times each website was listed as a source in these answers
In the study as US-listed.
- Is it worth enrolling in clinical trials for new medicines for rare neurological conditions?
- What are typical out-of-pocket costs for advanced medications targeting rare neurological disorders in the US?
- Best medications available for improving daily living in Huntington’s or Rett syndrome
- What are the most promising new treatments for rare neurological disorders?
- Are there non-pharmaceutical alternatives for managing symptoms of rare neurodegenerative disorders?
- Options for families when standard treatments for rare neurological conditions are not effective
- How does financial assistance work for patients seeking specialty treatments for rare diseases?
- How do biologic therapies compare to small-molecule drugs for treating neurological disorders?
- How to handle side effects from newly approved therapies for rare diseases
- Are advanced therapies for rare neurological diseases usually covered by insurance?
- Gene therapy vs traditional medication for rare neurodegenerative conditions: which is more effective?
- What can I do if my neurological disorder medication isn’t working as expected?
- What are alternative therapies if first-line medications for neurological disorders fail?
- How might new treatments improve quality of life for caregivers of patients with rare neurological diseases?
- When should a neurologist consider innovative medicines for patients with limited treatment options?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.